Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bailiang Wang

Showing results (111-120 of 118) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 118 results.
Biomaterials|May 26, 2022
Killing three birds with one stone: Near-infrared light triggered nitric oxide release for enhanced photodynamic and anti-inflammatory therapy in refractory keratitisHengrui Zhang, Wenya Jiang, Yaou Peng, et al.
Molecular Cancer Therapeutics|December 7, 2018
Cooperative Effect of Oncogenic <i>MET</i> and <i>PIK3CA</i> in an HGF-Dominant Environment in Breast CancerShuying Liu, Shunqiang Li, Bailiang Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 25, 2024
Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft ModelsFunda Meric-Bernstam, Erkan Yuca, Kurt W Evans, et al.
Molecular Cancer Therapeutics|April 29, 2025
Efficacy of ATR kinase inhibitor elimusertib monotherapy or combination in tumors with DNA damage response pathway and other genomic alterationsKaushik Varadarajan, Christian X Cruz Pico, Kurt W Evans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 6, 2023
Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing CancersTimothy P DiPeri, Kurt W Evans, Maria Gabriela Raso, et al.
Breast Cancer Research and Treatment|April 28, 2012
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancersLibero Santarpia, Yuan Qi, Katherine Stemke-Hale, et al.
Oncotarget|January 22, 2015
Functional consequence of the MET-T1010I polymorphism in breast cancerShuying Liu, Funda Meric-Bernstam, Napa Parinyanitikul, et al.
Cancer Discovery|February 15, 2024
Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived XenograftsTimothy P DiPeri, Kurt W Evans, Bailiang Wang, et al.
Pageof 12

Showing results (111-120 of 118) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 118 results.
Biomaterials|May 26, 2022
Killing three birds with one stone: Near-infrared light triggered nitric oxide release for enhanced photodynamic and anti-inflammatory therapy in refractory keratitisHengrui Zhang, Wenya Jiang, Yaou Peng, et al.
Molecular Cancer Therapeutics|December 7, 2018
Cooperative Effect of Oncogenic <i>MET</i> and <i>PIK3CA</i> in an HGF-Dominant Environment in Breast CancerShuying Liu, Shunqiang Li, Bailiang Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 25, 2024
Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft ModelsFunda Meric-Bernstam, Erkan Yuca, Kurt W Evans, et al.
Molecular Cancer Therapeutics|April 29, 2025
Efficacy of ATR kinase inhibitor elimusertib monotherapy or combination in tumors with DNA damage response pathway and other genomic alterationsKaushik Varadarajan, Christian X Cruz Pico, Kurt W Evans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 6, 2023
Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing CancersTimothy P DiPeri, Kurt W Evans, Maria Gabriela Raso, et al.
Breast Cancer Research and Treatment|April 28, 2012
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancersLibero Santarpia, Yuan Qi, Katherine Stemke-Hale, et al.
Oncotarget|January 22, 2015
Functional consequence of the MET-T1010I polymorphism in breast cancerShuying Liu, Funda Meric-Bernstam, Napa Parinyanitikul, et al.
Cancer Discovery|February 15, 2024
Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived XenograftsTimothy P DiPeri, Kurt W Evans, Bailiang Wang, et al.
Pageof 12